RxDoctor Payments Data

Tara Holguin

Physician Assistant · Orange, CANPI 1417491721

Payments from drug & device makers

$5,590in general payments, 2019–2025

Across 269 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$784
  • Novo Nordisk$694
  • AbbVie$394
  • Amgen$380
  • Boehringer Ingelheim$266
  • Abbott$261
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$5,590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,590 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$239,295
TrulicityDulaglutide40$59,581
JardianceEmpagliflozin30$49,169
Synjardy XrEmpagliflozin/Metformin Hcl36$47,250
Trijardy XrEmpaglifloz/Linaglip/Metformin20$33,954
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$30,248
FarxigaDapagliflozin Propanediol20$26,480
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$21,538
MounjaroTirzepatide18$20,554
SynjardyEmpagliflozin/Metformin Hcl13$16,709
Tresiba Flextouch U-100Insulin Degludec27$13,189
TradjentaLinagliptin13$11,461
Repatha SureclickEvolocumab11$8,232
Tresiba Flextouch U-200Insulin Degludec12$7,804
Humalog Kwikpen U-100Insulin Lispro22$5,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$694$239,295164 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Tradjenta$266$158,543112 claims
Lilly USA, LLCTrulicity, Mounjaro$784$80,13558 claims
AstraZenecaFarxiga$93$26,48020 claims
AbbVieSynthroid$394$4,23335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →